Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces a definitive agreement to acquire Life Molecular Imaging Ltd. (“Life Molecular”), in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments. Life Molecular, a subsidiary of Life Healthcare Group Holdings Ltd (“Life Healthcare”), is dedicated to advancing novel Positron Emission Tomography (PET) radiopharmaceutical diagnostics.
Read the full article: Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350M to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market //
Source: https://www.einpresswire.com/article/776426187/lantheus-to-acquire-life-molecular-imaging-for-an-upfront-payment-of-350-million-to-accelerate-innovation-for-patients-in-the-growing-alzheimer-s